How much of your research lives and dies on the bench? Not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle.

Jan Hunik and Matt Baker from MosaMatrix discuss the practical challenges and lessons learned from spinning out a biomaterials company from academia. They explore the importance of quality standards in biotech startups, building a team with complementary skills, and the realities of developing reproducible 3D culture systems for modern research.

Topics discussed:

  • The critical gap between invention and reliable biomaterial products (00:40)
  • Building company culture around quality standards from day one (02:45)
  • Balancing scientific curiosity and business direction as co-founders (03:51)
  • The impact of university partnerships on early-stage company development (06:02)
  • Funding challenges and strategies for sustaining a biotech startup (06:47)
  • Advice for scientists on addressing real market needs versus pushing technology (07:50)
  • The importance of listening to customers and investors to find product-market fit (09:19)
  • Vision for scaling technology and breaking even in the next two to three years (10:06)
  • New frontiers in engineering living materials and animal-free biomaterials (12:04)

Smart insight: The MosaMatrix team believes good materials are key to unlocking advances in drug discovery, cellular agriculture, and engineered living materials. Their story is a testament to how integrating rigorous science, business discipline, and a razor focus on real-world needs can create the foundation for lasting innovation in biotech.

If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.

  • Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch
  • Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang

Connect with Jan Hunik and Matt Baker:

Support the show

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist. Innehållet i podden är skapat av David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist och inte av, eller tillsammans med, Poddtoppen.